Good afternoon, everyone. Welcome to the Curaleaf Holdings Incorporated First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one. To withdraw your questions, you may press star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Camilo Lyon, Chief Investment Officer. Please go ahead. Good afternoon, everyone, welcome to Curaleaf Holdings first quarter 2023 conference call. Today, we're joined by Executive Chairman, Boris Jordan, Chief Executive Officer, Matt Darin, and Chief Financial Officer, Ed Kremer. Before we begin, I'd like to remind everyone that the comments on today's call will include forward-looking statements within the meaning of Canadian and United States securities laws, which by their very nature involve estimates, projections, plans, goals, forecasts, and assumptions, including the successful integration of acquisitions and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements on certain material factors or assumptions that were applied in drawing a conclusion or making a forecast in such statements. These forward-looking statements speak only as of the date of this conference call and should not be relied upon as predictions of future events. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additional information about the material factors and assumptions forming the basis of the forward-looking statements and risk factors can be found in the company's filings and press releases on SEDAR and the Canadian Securities Exchange. During today's conference call, in order to provide greater transparency regarding Curaleaf's operating performance, we will refer to certain non-GAAP financial measures and non-GAAP financial ratios that involve adjustments to GAAP results. Such non-GAAP measures and ratios do not have a standardized meaning under US GAAP. Any non-GAAP financial measures presented should not be considered to be an alternative to financial measures required by US GAAP, should not be considered measures of Curaleaf's liquidity and are unlikely to be comparable to non-GAAP financial measures provided by the other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable US GAAP financial measure under the heading reconciliation of Non-GAAP financial measures in our earnings press release issued today and available on our investor relations website at ir.curaleaf.com. With that, I'll turn the call over to Executive Chairman, Boris Jordan. Boris? Thank you, Camilo. Good afternoon, everyone, and thank you for joining us to discuss our first quarter 2023 results. Since it has only been a few weeks since our last earnings call, we will take a slightly different tack today. Given all the negative sentiment around the industry, a lot of which is not really justified, I wanna focus on the many catalysts we envision both internationally and domestically. There are exciting things happening right now and many more on the horizon. These secular growth drivers often get lost in all the noise around federal reform and the challenging operating environment we are currently in. Today's equity valuations do not appropriately reflect the opportunity in cannabis as this is still a dynamic and fast-growing industry with a long and bright future. Matt will discuss the myriad of operational initiatives we are implementing to improve efficiency and reduce costs. We know that expanding our margins during these tougher times will leave us with well-positioned for highly profitable growth as the industry normalizes. Ed will close with a review of our quarter one results. Despite our commitment to efficiency, Curaleaf is very much a growth company, and our solid start to 2023 is evidence of just that. I'm pleased to report first quarter year-over-year revenue grew 14% to $336.5 million compared to $296 million last year, beating our guidance of low double-digit sales growth. Adjusted gross margin was 48% and adjusted EBITDA margin was 22%, both exceeding consensus estimates. Based on the productivity and efficiency measures we have implemented across the organization, we anticipate margins will expand throughout the year. We ended the first quarter with $116 million of cash in our balance sheet and generated $31 million in operating cash flow from continuing operations. Curaleaf has access to approximately $50 million in secured financing that can be used to bolster our working capital should the need arise. Since our fourth quarter call two weeks ago, I've been in Europe meeting with our international team, analyzing the business and contemplating new opportunities. Curaleaf is the only MSO that has embraced the massive European market, initially investing in the leading platform two years ago. It is enormously gratifying to see that the market is now rapidly advancing as we envisioned as evidenced by the 130% year-over-year growth in quarter one registered in our European operations. I'm even more excited about the revenue and profit of our international segment will contribute to Curaleaf over the next three years. This remains meaningfully underappreciated by the investment community, I suspect that as Germany launches and other countries follow suit, we will get more credit for these bold moves. While still evolving, Germany's draft regulations entail a two-pillar system. With Pillar 1 focused on expanding the medical market and Pillar 2 aimed at the adult use market. Pillar 1 is setting up to be a Goldilocks scenario for the established players like our recently acquired brand, Four 20 Pharma. Currently, 2/3 of the German market is comprised of just five players, one of which is our company, Four 20 Pharma, with a roughly 15%-20% share. There are an estimated 200,000 medical cannabis patients in the country out of a population of 84 million people. Many more citizens have applied for access only to be denied by the high barriers to getting prescriptions from a doctor. Under the current draft, Pillar 1 would immediately eliminate this friction for patients by removing cannabis from the narcotics list, thus allowing doctors to more freely prescribe, while also giving consumers the comfort of knowing they are not part of a monitored national database. This proposal would also allow digital telemedicine appointments and faster delivery times, simplifying patient access compared to the cumbersome in-person and paper-based process mandated today. Removing these hurdles would undoubtedly accelerate patient enrollment, just as we have seen in the U.S. when medical states expand the list of qualifying conditions. As we assess and plan for how this market may develop, we look at Germany and compare it to established U.S. medical markets such as Florida, which has a current penetration rate of 3.8%. Assuming a similar participation rate in Germany implies a total patient population of over 3 million people, which would be a 15-fold increase from today's levels. We are conservatively assuming total patient growth of 3x to 5x, which still implies a EUR 1.5 billion market opportunity over the next two years. We are investing ahead of this massive opportunity to drive share, and we intend to leverage the Four 20 brand, which is known for consistent high quality, high THC potency. Given that medical patients are eligible for insurance reimbursements in Germany, these assumptions may well prove quite conservative. Building a well-recognized brand in the medical market ahead of adult use will give us an advantage when the program is ultimately launched. In addition to our production coming out of Portugal, we have augmented our supply chain with an exclusive multi-year partnership with the leading Canadian supplier of high-end flower to ensure we provide the market with consistent high-grade product as the market accelerates. The U.K. market grew 75% year-over-year in quarter one. We continue to streamline the patient funnel process by incorporating technology and software, helping remove friction from customer acquisition. We are also bringing our latest product innovations from the U.S. to this market. Over the coming months, we will introduce our newly formulated edibles and medical vapes to the U.K., and there is nothing comparable to these products available there today. This should further cement our lead in this high-growth, yet still nascent market, and establish Curaleaf as the most well-known and trusted brand from day one. We are investing prudently today throughout our international segment, setting the stage for robust growth in 2024, 2025 and 2026 as cannabis adoption accelerates across Europe. I could not be more excited about this opportunity and feel highly confident that this will be a huge strategic advantage that we will ultimately pay big dividends for our shareholders. We also have many exciting growth drivers domestically, and Curaleaf is well positioned to capitalize on near-term, medium and long-term state-level catalysts. In Connecticut, our two adult use stores continue to ramp nicely, and we expect our other two stores to be approved within the next 30-60 days. In Maryland, we are eagerly awaiting the July 1st launch of adult use program. With four highly productive stores and a robust wholesale presence, Maryland will be a very good market for Curaleaf. New York is another important opportunity. This is a market where we have a long-held number one share position. Draft regulations came out last week, and while the OCM has offered some concessions to the existing ROs, the industry is demanding more. The current regulations are hurting the hemp farmers and CAURD license recipients they were designed to help. These arbitrary rules only benefit the illicit market, which is thriving in the absence of legal competition. We, along with other market participants, are steadfast in our legal position and look forward to a quick resolution so the legal market can grow equitably and thrive. We are hopeful that we can begin selling into the adult use market by Q4 in some form, which will be an important step towards elevating New York into a $5 billion market and the pinnacle of East Coast cannabis. Over the next two to three years, important Curaleaf states, including Florida, Ohio and Pennsylvania, are likely to convert to adult use. According to BDSA, these three markets combined are estimated to generate over $8.5 billion in sales by 2027, and we will be ready to capitalize. Beyond that, we have applied or will be applying for licenses in Texas, Alabama, Kentucky and North Carolina, which represent further growth opportunities that we are eagerly anticipating. We are committed to efficient expansion and highly profitable growth and believe that we are just beginning to tap into the possibilities of this rapidly emerging industry. We continue to expect 2023 revenue will grow low to mid-single digits compared to 2022 revenue of $1.3 billion and project solid adjusted EBITDA margins in the mid-20% range, resulting in free cash flow generation of $50 million-$60 million after anticipated investments of $70 million into our business. With that, I'll turn the call over to our CEO, Matt Darin. Thanks, Boris. Over the past 12 months, we have made significant strides in streamlining our business. Since I moved into the CEO role one year ago, we've moved decisively and with urgency to maximize opportunities in high growth markets while scaling back from structurally unsound markets. We are laser-focused on operating efficiencies in every aspect of our business, including our cultivation and processing operations, retail store productivity, and share services both in the U.S. and Europe. Exiting unprofitable states was a first step, but certainly not the last. We are establishing a lean asset base from which we will drive operating leverage, margin improvements, and cash generation. I will touch on three operational initiatives that are underway and that are already contributing to productivity and efficiency gains that will build throughout the year. These three initiatives are inventory management, automation, and genetics. First is inventory management. While our inventory increased slightly from the end of 2022 as we ramped up for 4/20 spring season and the launch of JAMS, our new edibles brand, we are taking a number of actions to right-size our inventory. We are in a strong position to execute on this critical priority with the strength of our retail business and ability to further leverage our own branded products. We are successfully increasing vertical mix in the battleground markets of Illinois, Pennsylvania, and Arizona. We are at or approaching the 40% regulatory limit in Illinois in most locations and are now exceeding 50% vertical mix in Pennsylvania with room to grow. There are catalysts on the horizon in the wholesale business as well, with new dispensaries opening in New Jersey and Illinois, growth in new adult use markets such as Connecticut, positive trends in Massachusetts and Missouri, and the pending adult use launch in Maryland. Strong inventory management starts with an excellent sales, inventory, and operations planning process. We've invested in systems and personnel that enables us to forecast demand and plan inventory production with greater precision. Our ERP implementation is progressing state by state and when complete will be the first system with real-time inventory data direct from all seed-to-sale systems. We continue to refine our cultivation methods to focus not only on overall yields, but the ratio of bud to trim with a focus on high-quality, high-potency bud and reduced trim output. I am pleased that both our potencies and bud to trim ratios are the best they've ever been with more opportunity for improvement. We are also reducing redundant or inefficient capacity to further optimize our cost structure. We've closed our Amesbury facility in Massachusetts, our Belmar facility in New Jersey, and our Homestead outdoor grow in Florida, three older sites that have been replaced by newer, more efficient facilities. We will be continuously evaluating each site to ensure they are earning their cost of capital. While we have more work to do, I am confident in our plan to reduce inventory and to match demand to production. Second, we continue to invest in automation equipment in our tier one markets where the return on investment is measured in months, not years. The landscape of automation options has improved significantly over the past several years, and we have automated numerous processes in our supply chain from cultivation, pre-roll vape and edibles production, and packaging. We have migrated to Mylar bags for most products and will continue this move to reduce cost and environmental impact. In Florida, we're already seeing the benefits of a state-of-the-art vape filling and capping machine, and we'll be rolling this out in Massachusetts and Arizona soon. In New Jersey, we've automated gummy filling and packaging in anticipation of the launch of the JAMS edible line in early third quarter. In aggregate, the savings to our COGS from automation is estimated at $15 million over the next 12 months. That's over 100 basis points of gross margin contribution. Third is our focus on genetics and strain diversity. We are centralizing our breeding process for greater efficiencies around our new genetics program and also introducing new high-potency strains with unique proprietary genetics. We have a very robust pipeline of new genetics that are in production but have not yet hit the market, some of which are unique cultivars exclusive to Curaleaf. We are using the same innovative approach we've pursued in other product categories and applying it to cultivation. This effort will reduce our third-party purchases as we create a more diverse rotation of flower strains, something we know our consumer likes. These actions are central to achieving operational excellence. While changes will happen over the course of the year, investments we are making today create a solid foundation that positions us for long-term success. I would like to address our progress on cost savings and expense controls. We exceeded our cost savings initiative of $60 million and continued to reduce expenditures in COGS and SG&A. We are leaving no stone unturned as we attack every expense category from travel and entertainment to third-party lab testing and more. With that said, we are continuing to invest where needed. We are spending considerable time and money advocating for our industry in Washington, D.C., as we inch closer to federal reform. While this comes at a cost, this is what industry leadership looks like to us, and it's the right and necessary investment to make for the advancement of our industry. We call on the other leaders of our industry to step up and do their part as well. Shifting gears, I want to briefly touch on a few state highlights during the quarter. We are seeing strong trends in our retail business. We completed 3.33 million transactions in the first quarter, serving 934,000 customers and sold 10.3 million units. Despite the challenging macro environment and continued pressure on pricing and average order values, we are seeing positive movement in a number of key markets. In Arizona, we had a record-breaking quarter and are exceeding our internal projections. AUR for Curaleaf increased mid-single digits, while market pricing according to BDSA was down sequentially. We are seeing strong performance in a number of Northeast markets. New Jersey increased 55% year-over-year. We launched Grassroots and Find. to strong reception, and our Bordentown location continues to ramp well since opening in November. In Connecticut, we converted two of our stores to adult use, with our remaining two set to open over the next 30 to 60 days. Adult use sales in this state also continue to show a solid ramp as awareness increases and we expand our product assortment. In Massachusetts, AUR for Curaleaf bucked the market trend, increasing in Q1 compared to the overall market that continued seeing sequential price declines. We attribute this to the introduction of Grassroots as demand for high-quality flower is strong and selling out. We see many positive indicators in our business that reinforce our growth-focused strategy. Coupling this with the work we are doing to tighten up all aspects of our operations, including retail, wholesale, cultivation, and production, will propel us down the path of higher profitability and cash generation over the coming quarters and years. The future is bright for Curaleaf. With that, I'll turn the call over to our CFO, Ed Kremer. Ed? Thank you, Matt. Today, I'll review our Q1 2023 results and provide an update on our outlook. Total revenue for the first quarter was $336.5 million, representing a year-over-year increase of 14%. Growth was driven by New Jersey adult use, Arizona retail strength, the addition of Tryke, new store openings in Florida, and 53% growth in our international segment. By channel, retail revenue was $273 million compared to $225 million in the first quarter of 2022, up 21% year-over-year. Wholesale revenue decreased 11% year-over-year to $62 million and represented 18% of total revenue. Looking at our consumer metrics, transactions remained healthy in the first quarter and were up 14% sequentially from Q4, partially offset by a 7% decline in average order value. Our first quarter gross profit was $161 million, resulting in 48% gross margin. Adjusted gross profit was $162 million. Sequentially, Q1 adjusted gross margin decreased 80 basis points compared to the fourth quarter, largely due to price compression in certain markets. SG&A expenses were $112 million in the first quarter and increased $12 million from the year-ago period. The year-over-year increase in SG&A primarily reflects operating expenses associated with the addition of Tryke, Four 20 Pharma, and new store openings. SG&A, as a percentage of revenue, was 33% in the first quarter, down 60 basis points compared to the year-ago period. Our first quarter SG&A included approximately $8 million of ad backs versus $6 million in the prior year, with the increase driven by consulting and legal fees associated with our GAAP conversion process and expenses associated with acquisitions. Our core SG&A rate in Q1 was 31%, a decrease of 110 basis points year-over-year, as we are beginning to realize some of the benefits of the expense reduction actions we began taking in November, coupled with leverage on stronger sales. First quarter net loss was $56 million, which included $10 million of losses from discontinued operations. Net loss per share from continuing operations was $0.06. Adjusted EBITDA for the first quarter was $73 million compared to $76 million last year, a 4% decrease, resulting in EBITDA margin of 22% and 26% respectively. Sequentially, our adjusted EBITDA margin decreased 60 basis points from Q4 due to gross margin contraction. Turning to our balance sheet and cash flow. We ended the quarter with cash and cash equivalents of $116 million. Inventory from continuing operations increased $20 million or 8% compared to the fourth quarter, largely driven by a build ahead of Four 20 Pharma and the launch of our JAMS, our new edibles line. Net capital expenditures in the quarter were $26 million. We expect CapEx spend to be front half loaded and then decelerate in the back half of the year. As Boris and Matt mentioned, we are prudently investing today in the future growth opportunities we see across the international and domestic landscape. We continue to expect 2023 CapEx to be approximately $70 million or half of last year's expenditures. Our outstanding debt was $594 million, net of an amortized debt discounts, of which 80% is not due until December 2026. We ended the fourth quarter with 718 million fully diluted shares outstanding. We generated $14 million of cash flow from operations, excluding a $16 million use of cash from our discontinued operations. Cash flow from continuing operations was $31 million. Free cash flow from continuing operations was $5 million. While we are comfortable with our ability to fund our growth initiatives and pay all of our obligations, the company has access to approximately $50 million of secured financing that can be used to bolster our working capital should the need arise. We are off to a good start for the year and demand for cannabis remains robust. The current operating environment still presents its share of headwinds, such as elevated promotional activity in various states. We are well equipped to navigate these bumps in the road, yet we're also mindful of the pockets of distress in the market. As such, we are reiterating our fiscal 2023 guidance of low to mid-single digit revenue growth versus comparable $1.3 billion revenue base in 2022, which excludes discontinued operations. We continue to expect full year adjusted EBITDA margin to be in the mid 20% range. For Q2, we are comfortable with the current consensus estimate of approximately $340 million in revenue, which represents comparable year-over-year growth of 4% versus Q2 of 2022 revenue of $327 million, which excludes discontinued operations. We continue to expect to generate over $100 million in operating cash and $50 million-$60 million in free cash flow this year, with inventory work down being a key driver of overall working capital improvement. To this point, we expect to see inventory as a percentage of sales to improve to 15%. Lastly, I want to reiterate that the cadence of our cash flows will trough in Q2 after making tax payments and paying the balance associated with this year's Bloom obligation. Cash will begin rebuilding in Q3, with Q4 representing the largest cash generating quarter. With that, I'll turn the call back over to the operator to open the line for questions. Ladies and gentlemen, we'll now begin the question and answer session. To ask a question, you may press star and then one on a touch-tone telephone. If you are using a speakerphone, we ask that you please pick up the handset before pressing the keys. To withdraw your questions, you may press star and two. We also ask that in the interest of time, you please limit yourself to one question and a single follow-up. At this time, we'll pause momentarily to assemble our roster. Our first question today comes from Aaron Grey, from Alliance Global Partners. Please go ahead with your question. Hey, good evening. Thank you for the questions. First one for me, I wanna ask a high-level one, Boris. You know, in the past, we've spoken towards a balance of kind of market share and top-line growth, which you had been big on, and then a little bit more of a shift to margin just 'cause what's happened in the marketplace. Obviously we've seen this shift more recently as you exited some investment markets and increased verticalization. Wanna get some more color in terms of, you know, how you look to balance that in your existing markets going forward to drive market share gains, particularly from more of a wholesale perspective as these states start to normalize. What it gets you more comfortable doing that, just given the current dynamics. Thanks. I will give a macro picture and I'll hand over to Matt to see if he runs the business day-to-day. What we've done is we've just made an alignment, given market circumstances, to focus right now on building up our margins in order to generate cash. Cash is important in the current environment, as we said, we intend to finish the year with, you know, $50 million-$60 million of free cash after all the what are relatively heavy obligations during this year on both tax and on some of the acquisitions we've made. We think that's a good result of getting to that mid 25% level. However, we, as I started the call today, we are really focused on growth and the growth opportunities maturely going into 2024, 2025 and 2026 are quite substantial. We still have significant CapEx that we're making this year, and to the tune of $70 million, really focusing primarily on our European assets, but also continuing to build out in those markets like Arizona and Florida and others where we have significant market share and where we feel we can grow our market share further. Matt, I don't know if you wanna add to that. You know, specifically on the wholesale side, you know, we're certainly focused on some of our key markets where we are seeing new doors open, specifically New Jersey and Illinois and, you know, really focused on capitalizing that on those opportunities and, you know, been continuing to be focused on rounding out our brand portfolio. That's why we've launched the JAMS edibles line and a number of other different, you know, products across the segment there. I can also say we are seeing some real positive signs in a few markets that have had its challenges over the past number of quarters, you know, namely Massachusetts. Massachusetts is a market that got very oversupplied but we're now seeing some really strong opportunities when we have our Grassroots flower, when that hits the menu, it's sold out in a matter of hours. Seeing some real opportunities to kind of ramp up into that. Also seeing markets like Missouri, that has been a great success story, we just see huge wholesale opportunity in the Missouri market as that continues to grow into $1 billion market, so. Okay, great. Thanks for that color. Quick follow-up for me just in terms of, you know, New York regs. I know you mentioned in your prepared remarks, you know, obviously updated regs came out. Seems like you're not fully satisfied, you know, it will open some stores sooner, still has a pretty high conversion fee. You know, how do you think about, you know, the timing of when you might get some type of resolution, and have they been receptive towards that? How big of a factor would it be to their ability to crack down on the illicit market in terms of making it appealing for your decision to then participate and pay that conversion fee to come to the New York adult use marketplace? Thanks. I think that's, you know-- p laying a big role. That fee that they want to charge, you know, from our perspective, there's no enforcement on the adult use market. It's going to be very difficult to pay any fee in New York with the illicit market, you know, going crazy. I mean, we've seen some movement from the from the governor with new legislation, regulations posted, giving the regulator more rights to enforce. Frankly, we thought they had them from the very beginning anyway. We still do, and it's really a question of whether or not they're prepared to do that. The one good news is, at least on the East Coast, what we've seen is once the adult use market gets going, the legal adult use market, once there's a significant amount of penetration with good quality stores and good quality product, you do start seeing people migrating over to the legitimate market for a whole host of reasons. Both the fact that they don't want to break the law, but more importantly, they want to have product that can be tested. You probably all saw recently, you know, there's been articles about cannabis out there being laced with fentanyl. You're not gonna find that in regulated stores. I do think that the more we see unfortunate things like that, you will see people migrating to the stores. Regarding the negotiation, yes, we're not pleased at the moment because the state isn't even fulfilling their legal obligations of the law that they passed. All we're asking the state to do is to actually abide by the laws that were passed in the state, you know, two years ago when the adult use program was originally approved. That's where we're having our issues. We are making progress. We're negotiating with them. They've already made some moves here when they published the rules. As you know, those rules are now in comment period. We will be in negotiations with the state. We hope over the next month or so that we will come out with a program that we think hopefully the, between the state and ourselves, that's equitable, addresses the issues the state has, addresses those issues that we have, and will let us get into the market here, in the fourth quarter. The state, New York needs wholesalers. I think that the state really needs companies like Curaleaf to get their products on the shelves because the quality of the products on the shelves today, is very, very low because it's largely being grown in outdoor hemp farms. It doesn't meet the criteria that the customers want and the state wants. I think there's impetus and incentive on both sides to try to get the program launched. It's a process, and we're going through that process now. As I said in the call, we do hope that, in one form or another, wholesaling, a little bit of retail, but we should get going here in the fourth quarter, as, you know, assuming negotiations go well. Appreciate that color. Very helpful. I'll jump back in the queue. Our next question comes from Matt McGinley from Needham. Please go ahead with your question. Thank you. Thanks for the color on the inventory plan for the year. You already noted the drivers of the increase in the first quarter, I just wanna make sure that is the first quarter gonna be the peak for those inventory levels? Then on taxes payable, last year, I think your payments were about $108 million, and your net taxes were around $60 million with the deferrals. Do those amounts look similar this year? Yeah, Matt, thanks. This is Ed. The latter part of your question is yes, and the first part of your question is also yes. With the inventory levels are at their highest at the end of the first quarter, we believe, and will expect to unlock upwards of $40 million of working capital lift just from our inventory by the end of the year. We've already seen it to start to come down in April, and we continue to take that down as we thin out our rooms, as we reduce our inventory from the conversion to finished goods that we built up to support these launches. We will continue to drive that inventory down as the key initiative, and we're already seeing those results. Great. Assuming that the ballot initiative in Florida passes the Supreme Court review and will be on the ballot in 2024, what are you doing today or preparing to do to work in concert with the other operators in the state to build the support for that to pass? I know that 1 operator funded the entire signature campaign, and I guess I'm a little concerned that if there isn't more of a group effort, you all might not learn the lesson that it should be a coordinated effort until it fails on Election Day. You noted the leadership you're providing at the federal level and the expense around that. What are you doing to further this, to make sure that it gets through in Florida? Well, I think, Matt, I'll start, and I'll let Matt add to it. Obviously, we are very, very for adult use launch in Florida. Curaleaf has historically taken the brunt of a lot of the lobbying not only at the federal level, but a lot of the state levels. Our expenditures run very, very high compared to other companies. Obviously, Trulieve is the largest operator in Florida, has taken the mantle in Florida. We are definitely in coordination in terms of our support in terms of getting signatures to our stores. We are very supportive of everything that Kim is doing, but we kind of feel that we've borne, you know, at least from a financial perspective, that we have done a lot around the country. If you add up everything we've done at state levels, whether it be New Jersey, New York, and other places, you know, we're leading in New York, we led in New Jersey, we were very aggressive in Illinois and obviously Arizona. We've done our bit to get a lot of these states and spent real dollars in those states as well as at the federal level. You know, we have very significant dollars going this year, again at the federal level, for spending. I think the industry, there's some players that are, you know, taking the mantle in one location, others in another location. We are very, very supportive of everything she's been doing, and we'll continue to support it through whatever means we can. Financially, our focus has been federal and other states. Okay. Thank you. Our next question comes from Scott Fortune from ROTH MKM. Please go ahead with your question. Yeah, good afternoon thanks for the questions. I appreciate the color on the international side for us, just want to get a sense for kind of that segment, the emphasis there, and how much of that is spending for CapEx. You know, you have a $70 million budget in CapEx for the year, how kind of step us through the CapEx needs to build that out ahead of, you know, primarily the 2024 ramp in revenues from that standpoint, that deal. What we did to meet our obligations for 2024, given the bounce we expect, particularly in Germany, but also with the accelerated growth in the U.K., is that we did two things. The first is we're investing in our Portuguese facility. We will shortly be announcing a transaction in Portugal to increase our capacity on the particularly on the drying and processing side, because we have to be E.U. GMP certified. We are about to do something in that space. You'll hear from us. We also just literally this week signed a long-term agreement, a multi-year agreement with one of the largest providers of E.U. GMP-certified flower coming into Europe now, and we signed that on an exclusive basis. There will be... You know, that will help us dramatically. It will actually create a shortage for other players, because up until now, they've been supplying many other players. We sort of took the initiative to sign a deal with them. That way, at least over the next 24 months, while we continue to build out our facilities in Portugal, we have supplied enough flower and product, on about a 50/50 basis, where we'll be providing about 50% of the product ourselves through our facilities, and we'll be bringing in 50% on a multi-year contract that we signed with one of the biggest providers from Canada. We're fully ready for what we think will be a 3x to 5x increase in our market, in Germany. As I said, the numbers could make that much bigger, we're anticipating about a 3%-5%, we're trying to be conservative, increase. Our U.K. business continues to grow at, you know, over 100% per year every year. That's continuing to accelerate as well. We feel like right now we have the product supply, either it be through our contracts or through our facilities in Portugal, to be able to supply the market. Okay. Just to follow, keep on that, to follow up on that. The key has been the access, right? There seems to be the demand there. You know, from a medical, you get a prescription, and you have to see a specialist to get that reimbursed. You're saying the steps that they're taking for telehealth, that you're going to be able to have more doctors with that education now to start prescribing, you know, and since to direct for the medical side. Can you kind of step us through those two? The amount of doctors that are going to be prescribing is going to, you know, quintuple compared to what it is now. More importantly, I think that there was a couple of 100,000 patients that got rejected by the program because of the restrictions on the program today. Those restrictions are being lifted. There's only 300,000 patients, period. Those restrictions will be lifted. Even without further marketing or awareness, you're going to get almost a doubling overnight because of all the people that have been rejected by the program that obviously went to the illicit market because of the difficulty in getting a prescription in Germany today. We're very confident that between the increase in doctors and telemedicine, our goal to be fully digital, you won't need physical documents anymore. And there are several companies that are already up and going, like Algea Care in Germany, that are already operational today on the basis of what the government is regulating, that will almost immediately be able to start providing both doctors and marketplaces to sell products. We're very. I think the market in Germany is getting ready. The key problem in Germany is gonna be product, because E.U. GMP certification is very difficult to get. A lot of product failures, et cetera, which is why we've really focused the last two years, especially the last six months since legislation started to be discussed, in making sure we had the supply chain to meet that demand. Those companies that are gonna have the product are gonna be the ones that are gonna win. What we're really doing is trying to make sure our brand is front and center so that as we move into adult use in 2026 and 2027, you know, our brand will be very well recognized in that very large market. Thanks. I really appreciate the color. I will jump into the queue. Our next question comes from Yewon Kang from Canaccord Genuity. Please go ahead with your question. Yeah, good evening, everyone. This is Yewon Kang. On for Matt Bottomley. Thank you for taking my question. I just wanted to start talking about with the results of this quarter. On a sequential basis, wholesale revenues came down by 8%. Now that the wholesale operations have been pulled out of some of the unprofitable states like California, Colorado and Oregon, I guess could you comment on which markets contributed to the overall sequential decline? If the trend of declining wholesale revenues continue, do you foresee more pullbacks from additional states in the future? You know, as it relates to the wholesale business, you know, as we've talked about previously, you know, one of our top focuses is vertical mix in our retail stores and really, you know, working behind the strength of our retail business, which we continue to see, you know, really positive signs just in terms of traffic and. Different trends. You know, that continues to be a top priority in an environment where, you know, many of the wholesale markets are still working through, you know, oversupply in a bunch of different areas. With that said, I, you know, do believe there are going to be opportunities in a number of different markets for wholesale expansion. There's a dynamic at play where you have a number of markets that have not had new dispensaries open up in large quantity, you know, for several years now, but those are starting to happen in some of our strongest markets, places like New Jersey, and Illinois, as two examples. You know, we're also looking forward to some catalysts on the horizon with Maryland and, you know, really exciting wholesale opportunities as that adult use market comes online on July first. Continued opportunities in places like Connecticut as well, with that adult use market that continues to ramp up as you see more product assortment and selection. I do see, you know, strong opportunities, you know, to continue to build back that wholesale business, as we exited some of those, you know, western markets and have really kind of focused the business on more profitable, you know, sustainable markets. Okay. If I could just follow up to that question with regards to the margins, especially with the balance of the year. In relation to the gross annualized run rate savings of $60 million, could you speak on the split of this number between SG&A and COGS? I guess just wanted to gain some insight there in terms of how we should think about the margins going forward for the rest of 2023. Yeah, Yewon, I'll take that. Thank you for the question. Look, it's, there's certainly savings above the line and below the line that you should think about it in terms of probably more like 1/3 above, 2/3 below, give or take, in terms of sort of the breakdown of where the cost saving is coming from. That's just on a run rate basis, right? We obviously have additional expenses associated with the acquisitions that we brought on. Okay. Thank you for the color. I'll jump back into the queue. Thank you. Our next question comes from Andrew Partheniou from Stifel GMP. Please go ahead with your question. Hi. Good evening. Thanks for taking my question. Maybe continuing on the margin, focusing on gross margin here. You've got a few moving parts, the inventory monetization, cost savings, and maybe more sales in higher margin states. Wondering if you can kind of compartmentalize this or maybe discuss, you know, how should we think about this. Could your cost savings potentially offset any potential pressure from inventory monetization? You know, more sales in Illinois and New Jersey, higher margin states, could give you that margin lift, or is there another way that we should be thinking about this? Maybe more specifically about Illinois and New Jersey, if you could talk about how many new stores do you think could open this year? Yeah. Let me take the first part and I'll let Matt answer some of the, I guess, the part around the store growth. The way you should sort of think about it, Andrew, is there's a couple of things, right? I mean, you'll see that our increase in vertical mix continues to improve. We've certainly seen that in Illinois. We continue to drive that up and get it right up to the regulatory cap. We're improving our vertical mix in Arizona and other states. You know that Maryland is coming online. Coupled with that vertical mix offsetting obviously the wholesale softness, we're also investing part of the CapEx that we mentioned in automation, right? There's a lot of automation coming on board that's gonna continue to unlock gross profit above the line. Mitigating certain, you know, obviously offsetting things there that will improve as the year goes on. Really it's a vertical mix story and our geographic diversity of footprint that allows us to do that. I'll let Matt answer the second part. Yeah, the second part, look, in Illinois, out of 185 new licenses, I think there's approximately, you know, 20 that have gotten open so far. There's many more that are in various stages. Obviously, the delays from litigation and that's really slowed that down. You know, I think you're gonna continue to see, you know, stores open up on an incremental basis as they get built out and inspected and approved. I would expect you're gonna see, you know, double-digit additions, you know, to that list as time goes on. I think similar in New Jersey. You know, you have a lot of people that are currently, you know, working on building out locations and, you know, finishing doing that pre-work. I would expect, you know, to continue to see that ramp up as we get into the year. You know, those are many people that we've been working on discussing supply and, you know, kind of being able to make sure that we can, you know, service their shelves as they get opened. You know, I do anticipate we're gonna see, you know, quite a bit of new stores opening up in both those markets over the next 12 months. Okay, thanks for that. Thanks for that. Thinking about your cost savings overall, understanding the $60 million number is a gross number. You know, thinking about how that could translate to a net number considering that you're still investing in growth markets, you know, you still have some costs that you're taking on from new acquisitions or recent acquisitions. I'm just wondering how should we thinking about, for example, the SG&A line, you know, where we can see cost savings there. Is there potentially, you know, any color that you can provide on synergies from acquisitions that you've recently closed? I mean, Andrew, again, on the SG&A line, you should see the improvement that's already happened in Q1, and that's going to continue to build. I mean, we levered our SG&A by about 110 basis points, improved it over the fourth quarter sequentially. You can see it start to flow through. I'm sorry, year-over-year, not sequentially. I apologize. Year-over-year. You can see it starting to flow through already, and that's gonna continue to build. You know, obviously, we didn't have the full impact of that in the first quarter as some of the cuts that we undertook really was, you know, towards the end of January, beginning of February. You're gonna see a full quarter benefit of it in Q2 and on. you know, we expect to continue to improve on those. Thanks for that. I'll get back in the queue. Thanks, Andrew. Once again, if you would like to ask a question, please press star 1. Our next question comes from Eric Des Lauriers from Craig-Hallum Capital Group. Please go ahead with your question. Great. Thank you for taking my questions. I'll try another question on the margins first. Just as we think about EBITDA margins expanding throughout the year and then, you know, ending the year at that mid-20s, just wondering if there's any specific markets to call out that might be driving the bulk of that margin expansion throughout the year. Appreciate the color that you've given on some of the, you know, more granular projects that you're working on and whatnot, and some of the other drivers. If we could sort of narrow it down to the specific markets driving that'd be helpful. Thanks. Yeah, look, I think it runs the gamut, of, you know, especially, you know, kind of what we call our Tier 1 markets, where as we continue to leverage our ability to, you know, showcase our own products in our stores, markets like Arizona, where we have 16, you know, high performing locations and, a lot of, opportunity to continue to, increase vertical mix. Markets like Illinois, where we've made a lot of progress and, as I mentioned, on the call, we're, you know, really at that 40% regulatory limits in our locations there. You know, Pennsylvania, where, you know, we're really kind of at our highest, you know, vertical mix that we've ever been and continued opportunities to do that throughout the 18 locations. Those are three examples of markets where as we continue to, you know, focus on that piece, along with identifying operating efficiencies. I mean, those are the markets that we are most investing in automation, where we've really centralized operations and have found, you know, more cost savings and, you know, with more to come, and that we're really driving, you know, a lot of margin expansion. All right. That's very helpful. I appreciate that. The next one from me, so as you're implementing the ERP system, I guess one, when do you expect that to be sort of completed here? Then, as you sort of, you know, utilize that to help plan inventory and whatnot, just wondering how you're expecting your mix of, you know, premium versus value products to trend throughout the rest of the year. Thank you. Yes. The ERP projects, you know, ongoing. We're continuing to roll that out really in phases. You know, as we mentioned, I think it's the first ERP that's, you know, live with each of the seed-to-sale systems. A lot of work has gone into and continues to go into to that piece. You know, we're continuing to roll that out here. It's gonna be, you know, continue over the next three quarters especially, and we're phasing that out, you know, kind of in a few markets at a time. Looking as we get into the end of the year to have that implemented. On the premium versus value, you know, look, I think we're hitting both ends of the segment. I think we're seeing a couple different trends. First of all, there continues to be a huge focus on the value segment. you know, people continuing to trade down and looking for, you know, value offerings, and that's why we're seeing really positive results with the Find. brand that we've launched and continue to launch in a number of different states. you know, Select Essentials, which is our, you know, more value-oriented vape offering, which has been one of our most successful, you know, products in our portfolio. Continued attention on the value offering, which we're seeing consumers want to continue to attract to those. On the other side, we are also seeing strong demand on the premium side. The premium consumer is willing to spend a premium price for a high quality product. As we continue to roll out Grassroots in a number of different markets, as we're focused on products like our Live Rosin vape products, you know, we're seeing continued opportunity to expand into those. That premium consumer that is willing to pay, you know, kind of a very strong price, you know, as long as the quality is there. I think both are opportunities on each ends of the barbell for us to continue to build on. All righty. Thank you very much. Our next question comes from Mike Regan from-- Actually. With that, we'll be concluding today's question and answer session. I'd like to turn the floor back over to management for any closing remarks. Thank you, everybody, for listening on the call, and we'll look forward to speaking to you at the end of the second quarter. Ladies and gentlemen, with that, we'll conclude today's conference call and presentation. We thank you for joining. You may now disconnect your line.